Work in Progress: Drugs in Development.
Clin Liver Dis
; 22(3): 501-515, 2018 08.
Article
em En
| MEDLINE
| ID: mdl-30259849
ABSTRACT
Primary biliary cholangitis is an archetypal autoimmune disease that causes cholestasis, fibrosis, and liver failure. Ursodeoxycholic acid and obeticholic acid are approved for its treatment. Not all patients respond, some are intolerant, many have ongoing symptoms, and new therapies are required. Herein we describe drugs in development and potential future biological targets. We consider compounds acting on the farnesoid X receptor/fibroblast growth factor 19 pathway, fibrates and other agonists of the peroxisome proliferator-activated receptor family, transmembrane-G-protein-receptor-5 agonists, and several immunological agents. We also consider the roles of bile acid reuptake inhibitors, nalfurafine, and fibrates in pruritus management.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácido Quenodesoxicólico
/
Ácidos Cólicos
/
Receptores Citoplasmáticos e Nucleares
/
Receptores Ativados por Proliferador de Peroxissomo
/
Fatores de Crescimento de Fibroblastos
/
Imunossupressores
/
Cirrose Hepática Biliar
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article